<DOC>
	<DOCNO>NCT01108887</DOCNO>
	<brief_summary>RebiSmart™ device electronic injection log monitor adherence therapy . Therefore RebiSmart tool administer Rebif multi-dose cartridge may improve patient satisfaction adherence therapy . The objective study evaluate adherence , effectiveness convenience treatment subject relapse multiple sclerosis ( RMS ) use RebiSmart self-inject Rebif multi-dose cartridge .</brief_summary>
	<brief_title>An Observational Study Assessment Adherence , Effectiveness Convenience Rebif® Treatment Relapsing Multiple Sclerosis Patients Using RebiSmart™ .</brief_title>
	<detailed_description>This observational , international , multicenter study plan conduct RMS subject use RebiSmart auto-injector 300 sit 15 country across Europe . The participate country Austria , Belgium , Czech Republic , Denmark , Estonia , France , Germany , Hungary , Lithuania , Portugal , Slovakia , Sweden , Switzerland , Netherlands United Kingdom . Subjects RMS naïve treatment currently treat Rebif multi-dose inject RebiSmart 6 week meeting eligibility criterion receive Rebif 22 44 mcg subcutaneously three time week . The dose Rebif titrate initial four week treatment . The planned observational period per subject 12 month . The study visit comprises : Baseline Day 1 ( Visit 1 ) , Month 6 ( Visit 2 ) , Month 12 ( Visit 3 ) . OBJECTIVES Primary objective : - To assess adherence treatment subject RMS use RebiSmart self-inject Rebif multi-dose cartridge Secondary objective : - To assess effectiveness convenience treatment subject RMS use RebiSmart self-inject Rebif multi-dose cartridge .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Males female subject 1865 year age ( Germany : Males females 12 65 year age order follow national medical society guideline ) Female subject must neither pregnant breastfeeding must lack childbearing potential define either : ) Postmenopausal surgically sterile , b ) Using highly effective method contraception duration study . This define method result low failure rate ( i.e. , less 1 % per year ) use consistently correctly , include instance implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) , sexual abstinence vasectomise partner Subjects diagnose Relapsing MS accord revise McDonald Criteria ( 2005 ) MStreatment naïve subject subject treat Rebif multidose inject RebiSmart longer 6 week prior Baseline visit Subjects able selfinject RebiSmart ( opinion physician ) Subjects Expanded Disability Status Scale ( EDSS ) score &lt; 6 ( inclusive ) Baseline Signed inform consent ( country subject signature mandatory : subject must give patient information ) Subjects experience relapse within 30 day Baseline Subjects participate study within 30 day Baseline Subjects receive MS therapy within 6 month prior study enrolment ( e.g. , disease modify drug : immunomodulatory , immunosuppressive agent combination therapy ) exception Rebif multidose inject RebiSmart Any visual physical impairment precludes subject selfinjecting treatment use RebiSmart Pregnancy breastfeed Serious acute heart disease uncontrolled cardiac dysrhythmias , uncontrolled angina pectoris , cardiomyopathy , uncontrolled congestive heart failure Current past ( within last 2 year ) history alcohol drug abuse Have contraindication treatment interferon beta1a accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>RebiSmart</keyword>
	<keyword>Rebif</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>